The Board of Directors has decided to proceed with the previously communicated business change. Against this background, Pharmacolog will convene an extraordinary general meeting in the manner prescribed by the Swedish Companies Act. The Board proposes a name change to Perpetua Medical AB (publ) and a new business direction, which includes the acquisition of smaller yet profitable companies in the healthcare sector. The background to this is that progress has been made regarding the investigation of a new business direction.
In February, Pharmacolog announced that the Board intended to investigate the conditions for a new business direction, which could include the acquisition of niche and profitable companies in the healthcare sector. Since then, the Board has been probing the unlisted market for company candidates where several interesting companies have already been identified.
The efforts to build such a business, and with a significantly different risk profile than the current business, is now entering the next phase. A number of interesting company candidates will be contacted. Within this framework, the Board has decided that an Extraordinary General Meeting will be convened to present a proposal for a name change and a change of business direction, both of which require changes to the Articles of Association.
Erik Hedlund, Chairman of the Board of Directors and main owner of Pharmacolog: “The proposal to amend the articles of association and the name change follows the progress we have made in evaluating the new business direction. We are now entering a new phase where interesting companies will be contacted and the work will be intensified. The proposed name change to Perpetua Medical AB (publ) reflects the ambition to build a group of independent subsidiaries in the healthcare sector through a decentralized and long-term ownership model.”
For more information contact:
Lars Gusch, CEO
Email: lars.gusch@pharmacolog.com
Phone: +46 70-223 97 72
About Pharmacolog
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, WasteLog™and Pharmacolog Dashboard™.
Further information regarding the company is available at https://pharmacolog.com/.
The company’s Certified Adviser is Mangold Fondkommission AB.
Release